JP6389177B2 - オランザピンハプテンに対する抗体及びその使用 - Google Patents

オランザピンハプテンに対する抗体及びその使用 Download PDF

Info

Publication number
JP6389177B2
JP6389177B2 JP2015528596A JP2015528596A JP6389177B2 JP 6389177 B2 JP6389177 B2 JP 6389177B2 JP 2015528596 A JP2015528596 A JP 2015528596A JP 2015528596 A JP2015528596 A JP 2015528596A JP 6389177 B2 JP6389177 B2 JP 6389177B2
Authority
JP
Japan
Prior art keywords
antibody
group
olanzapine
formula
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015528596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529201A5 (https=
JP2015529201A (ja
Inventor
リョホレンコ，エリック
サンカラン，バヌマティ
デコリー，トーマス，アール．
タブス，テレサ
コルト，リンダ
レメリー，バート，エム．
サルター，ライズ
ドナエ，マシュー，ギャレット
ゴング，ヨン
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2015529201A publication Critical patent/JP2015529201A/ja
Publication of JP2015529201A5 publication Critical patent/JP2015529201A5/ja
Application granted granted Critical
Publication of JP6389177B2 publication Critical patent/JP6389177B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
JP2015528596A 2012-08-21 2013-08-20 オランザピンハプテンに対する抗体及びその使用 Active JP6389177B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691572P 2012-08-21 2012-08-21
US61/691,572 2012-08-21
PCT/US2013/055817 WO2014031656A1 (en) 2012-08-21 2013-08-20 Antibodies to olanzapine haptens and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018153217A Division JP6721641B2 (ja) 2012-08-21 2018-08-16 オランザピンハプテンに対する抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2015529201A JP2015529201A (ja) 2015-10-05
JP2015529201A5 JP2015529201A5 (https=) 2016-04-28
JP6389177B2 true JP6389177B2 (ja) 2018-09-12

Family

ID=50148310

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015528596A Active JP6389177B2 (ja) 2012-08-21 2013-08-20 オランザピンハプテンに対する抗体及びその使用
JP2018153217A Active JP6721641B2 (ja) 2012-08-21 2018-08-16 オランザピンハプテンに対する抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018153217A Active JP6721641B2 (ja) 2012-08-21 2018-08-16 オランザピンハプテンに対する抗体及びその使用

Country Status (11)

Country Link
US (3) US20140057303A1 (https=)
EP (2) EP2887952B1 (https=)
JP (2) JP6389177B2 (https=)
CN (2) CN109400708A (https=)
AU (3) AU2013305895B2 (https=)
CA (1) CA2882595C (https=)
ES (2) ES3057437T3 (https=)
PL (1) PL2887952T3 (https=)
PT (1) PT2887952T (https=)
TR (1) TR201910347T4 (https=)
WO (1) WO2014031656A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
US9494608B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
CN104736565B (zh) 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
ES2652641T3 (es) 2012-08-21 2018-02-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
EP3462173B1 (en) 2012-08-21 2021-03-31 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
ES2788716T3 (es) 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
CN105601730A (zh) * 2014-10-30 2016-05-25 北京维德维康生物技术有限公司 呋喃妥因半抗原和抗原的制备方法及其在化学发光免疫试剂盒中的应用
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
CN110938082A (zh) * 2019-10-30 2020-03-31 杭州博拓生物科技股份有限公司 一种奥氮平人工抗原及其制备方法
CN114685527B (zh) * 2020-12-25 2024-03-05 长沙博源医疗科技有限公司 一种奥氮平衍生物、免疫原、抗奥氮平特异性抗体及其制备方法与应用
CN115073492B (zh) * 2022-08-22 2022-11-18 北京丹大生物技术有限公司 一种奥氮平衍生物抗原、奥氮平抗体及其应用
CN119662553B (zh) * 2024-11-26 2025-11-28 江南大学 一种分泌奥氮平类化合物单克隆抗体的杂交瘤细胞株

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228A (en) 1849-03-27 Coejsr-shelleb
US4022780A (en) 1973-03-06 1977-05-10 Imperial Chemical Industries Limited Process for the manufacture of indole derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
CA2101337A1 (en) * 1991-02-01 1992-08-02 Stephan D. Glenn Method of producing f(ab')2 fragments of immunoglobulins
DE69232002T2 (de) 1991-06-07 2002-06-06 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays unter Verwendung von markierten Hapten-Analogen
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5616505A (en) * 1992-03-27 1997-04-01 Abbott Laboratories Haptens tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids
DK0582368T3 (da) 1992-05-29 2001-02-05 Lilly Co Eli Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5527709A (en) 1992-06-26 1996-06-18 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays with labeled thyronine hapten analogues
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
CA2192467C (en) 1994-06-10 2009-03-31 Alireza Rezaie Calcium binding recombinant antibody against protein c
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
AU8148898A (en) 1997-06-23 1999-01-04 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
UA76708C2 (uk) 1999-12-08 2006-09-15 Сінгента Патисипейшонс Аг Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
AU2003217936A1 (en) 2002-03-28 2003-10-13 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
AU2003259256A1 (en) 2002-07-29 2004-02-16 Potomac Pharma, LLC. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
AU2003264915A1 (en) 2002-08-05 2004-02-25 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
US20040193446A1 (en) * 2003-03-27 2004-09-30 Mayer Steven Lloyd System and method for managing a patient treatment program including a prescribed drug regimen
US7271252B2 (en) 2003-04-22 2007-09-18 Roche Diagnostics Operations, Inc. Reagents for detecting efavirenz
CA2525251C (en) 2003-05-09 2015-10-27 Duke University Cd20-specific antibodies and methods employing same
BRPI0413595B8 (pt) * 2003-08-18 2021-05-25 H Lundbeck As sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto
ES2335589T3 (es) 2003-09-23 2010-03-30 Fermion Oy Preparacion de quetiapina.
CN101921279A (zh) 2003-10-01 2010-12-22 阿得罗公司 螺环杂环衍生物及其应用方法
DE602004024236D1 (en) 2003-12-12 2009-12-31 Inverness Medical Switzerland Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
WO2005103250A1 (ja) 2004-04-26 2005-11-03 Takami Matsuyama 葉酸リセプターベータ（FR-β）に対する単クローン抗体を含有する治療薬
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
WO2008082979A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
RU2010116351A (ru) 2007-09-27 2012-05-20 Новартис АГ (CH) Мониторинг лекарственных средств
US8133743B2 (en) 2007-10-19 2012-03-13 Roche Diagnostics Operations, Inc. Phenobarbital derivatives useful in immunoassay
EP2320942B1 (en) 2008-07-21 2018-03-14 Probiodrug AG Diagnostic antibody assay
EP2331088A4 (en) * 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
CN102245605B (zh) 2008-10-14 2016-01-27 阿斯利康(瑞典)有限公司 用于治疗细菌感染的稠合、螺环杂芳族化合物
EP2347015A4 (en) * 2008-10-29 2012-12-19 Janssen Pharmaceutica Nv METHOD FOR THE TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GEN
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
EP2389169A1 (en) * 2009-01-26 2011-11-30 Egalet A/S Controlled release formulations with continuous efficacy
EP2406289B1 (en) 2009-03-10 2017-02-22 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
US8076097B2 (en) 2009-08-19 2011-12-13 Saladax Biomedical Inc. Imatinib immunoassay
RU2595843C2 (ru) * 2009-10-16 2016-08-27 Омик Аб Способ анализа и устройства с применением магнитных частиц
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
EP3476218A1 (en) 2010-03-11 2019-05-01 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8114621B2 (en) 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
CN102260290A (zh) 2010-05-25 2011-11-30 苏州波锐生物医药科技有限公司 喹喏啉酮类化合物及其在制备精神病药物中的用途
WO2011159537A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
CN102276592B (zh) 2011-06-17 2013-10-16 大连理工大学 一种奥氮平有关物质及其制备方法、分析方法
CN102276624B (zh) 2011-06-17 2013-10-16 大连理工大学 一种奥氮平有关物质及其制备方法和高效液相色谱分析方法
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
SG11201501130PA (en) 2012-08-16 2015-04-29 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
ES2904838T3 (es) 2012-08-21 2022-04-06 Janssen Pharmaceutica Nv Haptenos de risperidona y paliperidona
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
US9494608B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
ES2822907T3 (es) 2012-08-21 2021-05-05 Janssen Pharmaceutica Nv Haptenos de quetiapina para su uso en inmunoensayos
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
EP3462173B1 (en) 2012-08-21 2021-03-31 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
ES2652641T3 (es) 2012-08-21 2018-02-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
CN104736565B (zh) 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
TR201816378T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Olanzapin haptenleri.
ES2788716T3 (es) 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
EP3588013A1 (de) 2018-06-26 2020-01-01 XelectriX Power GmbH Verfahren zur abgabe von elektrischer energie

Also Published As

Publication number Publication date
EP3581195B1 (en) 2025-10-01
CA2882595C (en) 2019-06-04
EP2887952A4 (en) 2016-04-13
ES3057437T3 (en) 2026-03-02
US20170343569A1 (en) 2017-11-30
PT2887952T (pt) 2019-08-30
JP6721641B2 (ja) 2020-07-15
US11226345B2 (en) 2022-01-18
US20140057303A1 (en) 2014-02-27
ES2733963T3 (es) 2019-12-03
PL2887952T3 (pl) 2019-11-29
EP2887952B1 (en) 2019-05-15
CN104755093A (zh) 2015-07-01
AU2013305895A1 (en) 2015-03-05
WO2014031656A1 (en) 2014-02-27
JP2019004889A (ja) 2019-01-17
US20170240653A1 (en) 2017-08-24
EP2887952A1 (en) 2015-07-01
AU2019283807A1 (en) 2020-01-16
TR201910347T4 (tr) 2019-07-22
CN104755093B (zh) 2018-11-16
US10712353B2 (en) 2020-07-14
HK1211857A1 (en) 2016-06-03
CN109400708A (zh) 2019-03-01
EP3581195A1 (en) 2019-12-18
AU2013305895B2 (en) 2017-10-19
AU2019283807B2 (en) 2021-04-29
CA2882595A1 (en) 2014-02-27
JP2015529201A (ja) 2015-10-05
AU2018200435A1 (en) 2018-02-08
AU2018200435B2 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
JP6389177B2 (ja) オランザピンハプテンに対する抗体及びその使用
JP6389176B2 (ja) アリピプラゾールハプテンに対する抗体及びその使用
JP6637580B2 (ja) クエチアピンハプテンに対する抗体及びその使用
JP6971927B2 (ja) リスペリドンハプテンへの抗体及びその使用
JP6423490B2 (ja) オランザピン（Ｏｌａｎｚｉｐｉｎｅ）のハプテン
JP2018118972A (ja) パリペリドンハプテンに対する抗体及びその使用
HK40018877A (en) Antibodies to olanzapine haptens and use thereof
HK1211857B (en) Antibodies to olanzapine haptens and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170221

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170308

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20180517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180717

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180816

R150 Certificate of patent or registration of utility model

Ref document number: 6389177

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250